Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Antiemetic, antihistamine
Original Date: 
August 2005
Revised Date: 
September 2011
  • Prevention and/or treatment of post-operative vomiting and drug induced nausea and vomiting
  • Symptomatic treatment of Menieres and other vestibular disturbances
Reconstitution and Stability: 
  • Available as 50 mg/mL ampoule
  • Stable at room temperature
  • Diluted solutions in D5W and 0.9% NaCl minibags are stable for 7 days at room temperature or 91 days in the fridge

- Solutions Compatible: dextrose solutions up to D10W, 0.9% NaCl, dextrose-saline combinations, ringer's solution, ringer's lactate

- Additives/Above Cassette Compatible: codeine, diphenhydramine, hydromorphone, KCl, morphine (for 15 minutes),  ranitidine

- Y-site Compatible: acyclovir

- Incompatible: chlorpromazine, glycopyrrolate, hydroxyzine, midazolam,  thiopental


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO  - except for Palliative Care Service

Usual dilution: 50 mg/mL

IV Direct

Usual dilution: 5 mg/mL
Infusion time: 5 minutes

IV Intermittent Infusion YES
Usual dilution: 5 mg/mL
Infusion time: 15 minutes
IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • 5 mg/kg/day IM/IV ÷ Q 6 hours PRN
    (Usual dose 1 mg/kg per dose)
  • Maximum dose:
    - 2-5 years: 12.5-25 mg Q 6-8 hours
    - 6-12 years: 25-50 mg Q 6-8 hours
  • Dose Limit: 50 mg/dose


  • 50 mg/dose IM/IV Q 4-6 hours PRN
Potential hazards of parenteral administration: 
  • Irritation/pain at IM injection site - rotate sites
  • IV irritating to veins and may lead to sclerosis
  • Should NOT be given parenterally to neonates (contains benzyl alcohol)
  • Paradoxical CNS stimulation may occur
  • Drowsiness, dizziness, dry mouth
  • Hypotension, palpitations, tachycardia
  • May mask symptoms of ototoxicity when given concomitantly with an aminoglycoside antibiotic or other ototoxic drugs 
  • Potentiates anticholinergics and CNS depressants                                        
  • Dimenhydrinate is composed of diphenhydramine plus another moiety; the effects of dimenhydrinate are believed to be from the diphenhydramine component

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.